JW Shinyak Corporation

A067290

KR7067290007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
1,815 ^KRW	+5.52%		-3.04%	-26.81%

Mar. 18	JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

JW Shinyak Corporation announced that it has received KRW 25 billion in funding

November 21, 2019

On November 22, 2019, JW Shinyak Corporation (KOSDAQ:A067290) closed the transaction.

Latest news about JW Shinyak Corporation

JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
JW Shinyak Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
JW Shinyak Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-16	CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
JW Shinyak Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
JW Shinyak Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
JW Holdings Corporation agreed to acquire additional 5.55459% stake in JW Shinyak Corporation for KRW 11.6 billion.	22-04-27	CI
JW Shinyak Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
JW Shinyak Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
JW Shinyak Corporation cancelled the acquisition of an additional 28.9% stake in JW CreaGene Co., Ltd. from group of sellers for KRW 30.7 billion.	21-01-15	CI
JW Shinyak Corporation agreed to acquire an additional 28.9% stake in JW CreaGene Co., Ltd. from group of sellers for KRW 30.7 billion.	20-01-16	CI
JW Shinyak Corporation announced that it has received KRW 25 billion in funding	19-11-21	CI
JW Shinyak Corporation announced that it expects to receive KRW 25 billion in funding	19-11-20	CI
JW CreaGene Co., Ltd. announced that it has received KRW 25 billion in funding from JW Shinyak Corporation	17-02-09	CI
JW Shinyak Corporation announced that it has received KRW 25 billion in funding from a group of investors.	16-03-29	CI
JW Shinyak Corporation announced that it expects to receive KRW 25 billion in funding from a group of investors.	16-03-27	CI
JW Holdings Corporation cancelled the sale of 4.61% stake in JW Shinyak Corporation.	12-11-03	CI

JW SHINYAK CORPORATION is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Companyâs main products portfolio consists of antibiotics, anesthetics, respiratory remedies, urology remedies, cardiovascular remedies, allergy remedies, digestive remedies, anti-inflammatory drugs, antivirals as well as acne remedies, among others. In addition, it also involves in the provision of cosmetics, such as creams, cleansers, toners, essences, lotions and others.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
JW SHINYAK CORPORATION	-26.81%	66.84M
KYOWA KIRIN CO. LTD.	+10.08%	9.12B
SK BIOPHARMACEUTICALS CO., LTD.	-15.94%	4.8B
YUHAN CORPORATION	+1.89%	3.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+18.47%	3.72B
INDIVIOR PLC	+25.99%	2.58B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-24.63%	2.36B
BETTA PHARMACEUTICALS CO., LTD.	-29.37%	2.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+2.55%	1.86B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B